Artiva Biotherapeutics, Inc.’s ARTV share price has dipped by 12.25%, which has investors questioning if this is right time ...

Research analysts at William Blair issued their Q1 2026 earnings estimates for shares of argenx in a research note issued on ...

Pemphigus is divided into two major subtypes: pemphigus vulgaris and pemphigus foliaceus. Oral corticosteroids are the primary treatment modality for pemphigus, while other therapeutic options ...

Equities researchers at William Blair issued their Q4 2026 earnings estimates for argenx in a report released on Monday, ...

Artiva Biotherapeutics' CEO Fred Aslan, MD, explains the strategic advantages of pursuing both a company-sponsored trial and an investigator-initiated trial simultaneously.

Having established success in cancer, biopharma is now looking to leverage CAR T therapies against a new target, autoimmune ...

Autoimmune bullous diseases are often associated with significant morbidity and some can even cause mortality, if left untreated. Multiple therapies are now available to treat these blistering ...

From wetting the bed to acne, we have crunched the numbers on the success rate of every single disability claim. It comes ...

Netherlands biotech Argenx has a second FDA approval for its FcRn inhibitor Vyvgart Hytrulo, adding a new indication in chronic inflammatory demyelinating polyneuropathy (CIDP) for a drug that it ...

After hours: March 17 at 7:06:39 PM EDT Loading Chart for CABA ...